A Hyderabad-based Ayurvedic and nutraceutical maker opens its Rs 26.50 crore BSE SME issue on September 22
Himalaya Nutravedics India Ltd (HNIL) operates in the Ayurveda and nutraceuticals space — a specialised segment of India’s pharmaceutical and wellness ecosystem — manufacturing, marketing and distributing Ayurvedic and nutraceutical formulations, and additionally undertaking third-party contract manufacturing for other Ayurvedic and nutraceutical companies.
It is a play on India’s growing preventive-healthcare, wellness and AYUSH demand. The product portfolio is diversified and dosage-form-rich. HNIL makes classical (Shastric) Ayurvedic formulations — based on traditional texts such as Charaka Samhita, Sushruta Samhita, Ashtanga Hridaya and Bhaishajya Ratnavali — alongside proprietary Ayurvedic formulations and nutraceutical products, across soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, medicated oils and protein powders.
These span therapeutic categories including digestive health, immunity, metabolic health and pain management, using ingredients like vitamins, minerals, herbal extracts and amino acids.
The model is a hybrid of own-brand plus contract manufacturing. HNIL commenced operations in September 2022, initially deriving revenue primarily from third-party manufacturing, and has since built up its own-brand business — which contributed around Rs 22.03 crore, or 51.14%, of FY26 revenue.
It markets its branded products through healthcare practitioners and has expanded to 17 states and one union territory.
Its integrated Cherlapally (Hyderabad) facility is WHO-GMP compliant with AYUSH and FSSAI registrations, plus ISO 9001:2015, ISO 22000:2018, HACCP, HALAL and KOSHER certifications. It was recognised as a DPIIT “Startup” in 2025, had 86 employees as of July 31, 2026, and the promoters are the founding promoter group.
Issue Details
| Particulars | Details |
|---|---|
| Issue Opens | September 22, 2026 |
| Issue Closes | September 24, 2026 |
| Listing | BSE SME |
| Listing Date | September 29, 2026 |
| Issue Type | Book Built |
| Price Band | Rs 100 – Rs 106 per share |
| Face Value | Rs 10 |
| Issue Size | Rs 26.50 crore (24,99,600 shares, entirely fresh) |
| Min. Application | 2,400 shares (2 lots; multiples of 1,200 thereafter) |
| Min. Retail Investment | Rs 2,54,400 |
| Post-IPO Market Cap | Rs 93.35 crore |
| IPO as % of Post-IPO Capital | 28.38% |
| Lead Manager | Nirbhay Capital Services Pvt. Ltd. |
| Market Maker | Allwyn Securities Ltd. |
| Registrar | KFin Technologies Ltd. |
The issue is entirely a fresh issue. From the net proceeds, HNIL will utilise Rs 13.75 crore for working capital, Rs 7.50 crore for investment in branding, digital marketing and sales expansion, and the rest for general corporate purposes.
Post-IPO, paid-up equity rises from Rs 6.31 crore to Rs 8.81 crore — a small base implying a longer gestation before mainboard migration.
At the upper band of Rs 106, on FY26 earnings the issue is valued at a P/E of about 12.63x, with a P/BV of 3.97 on the March 31, 2026 NAV of Rs 26.70, easing to 2.13x on the post-IPO NAV of Rs 49.66.
GMP
| Particulars (Rs cr) | FY24 | FY25 | FY26 |
|---|---|---|---|
| Total Income | 14.43 | 21.00 | 43.12 |
| Net Profit (PAT) | 0.43 | 2.23 | 7.39 |
| PAT Margin (%) | 2.95 | 10.63 | 17.16 |
| RoCE (%) | 17.00 | 30.18 | 36.41 |
The financials show explosive growth of questionable durability. Total income tripled from Rs 14.43 crore in FY24 to Rs 43.12 crore in FY26 (doubling in FY26 alone), and PAT surged from Rs 0.43 crore to Rs 7.39 crore — a more-than-17x jump in two years.
PAT margin exploded from 2.95% (FY24) to 17.16% (FY26), and RoCE to 36.41% (with RoE reported at ~64%).
The company reported an average EPS of about Rs 12.11 and a headline-high average RoNW of 38.88% (flattered by the thin equity base and the profit surge). Rising trade receivables year-on-year add a cash-quality concern; contingent liabilities were negligible at Rs 0.27 crore. The company has no dividend history.
The offer document lists Jeena Sikho and Sandu Pharma as peers, trading at P/Es of roughly 26.8x and 20.2x (as of September 18, 2026). These differ in scale and mix, so the comparison isn’t strictly apples-to-apples — HNIL’s ~12.6x FY26 P/E sits below both, but its ~42x FY25 P/E (the cleaner base) is well above, underscoring the aggressively-priced read.
Risks to Consider
Margin sustainability is the headline risk. PAT margin exploding to 17.16% in FY26 for a company barely three years old, with profit up more than 17x.
Aggressive valuation. On the cleaner FY25 base the P/E is ~42x, rich for a young, small Ayurveda/nutraceutical maker, leaving little cushion if margins normalise.
Very short operating history. HNIL was incorporated only in June 2022 and commenced manufacturing in September 2022 — so its standalone track record is short, and the rapid scale-up is recent and unproven across a full cycle.
Contract-manufacturing and own-brand balance. Nearly half of revenue still comes from third-party contract manufacturing (a lower-margin, client-dependent business), and the own-brand pivot is early; loss of contract clients or slow own-brand traction could hit results.
Receivables and working-capital intensity. Rising trade receivables raise a cash-conversion concern, and Rs 13.75 crore of proceeds funds working capital — an increasingly cash-hungry model as it scales.
